Thrombophilia has no specific treatment but it indicates that extra care may need to be taken to reduce the risk of thrombosis. This is a complex area . A finding of an abnormal thrombophila test result does not indicate that treatments should be changed or started in most cases. It is recommended that patients seek consultation with a haematologist with a specialist interest in thrombosis before they consider testing for thrombophilia or need advice about an abnormal result. Regardless of the cause of thrombosis and the presence of absence of thrombophilia, the treatment for an acute thrombosis is often fairly standard. It often consists of short term heparin (or, more commonly, low-molecular weight heparin) anticoagulant therapy, followed by an overlap of heparin and warfarin therapy, followed by several months or longer of warfarin therapy. this treatment regimen, unfractionated (standard) heparin is monitored using the PTT test or heparin assay, and warfarin therapy is monitored with the international normalized ratio (INR).
Newer drugs called direct acting oral anticoagulants (DOACs) are being used increasingly instead of heparin and warfarin.
After several months of anticoagulationyour doctor may evaluate your risk of clot recurrence. The doctor must weigh the risk of recurrent clotting against the very real risk of bleeding episodes with continued anticoagulation. If you are at a high risk of recurrent clotting, anticoagulant therapy may be continued indefinitely. If you are at a lower risk, the anticoagulant will most likely be discontinued but you will need to be vigilant, going back to your doctor promptly if thrombotic symptoms return. Thrombophilia tesing may help in this decision-making process, but often other factors are more important than the results of these tests